ASTRESSINA-B

Home Page Anagen.net Trattamenti medici e farmacologici contro la calvizie  Indice ragionato calvizie e capelli

Una molecola chiamata astressina-B, inizialmente studiata per limitare gli effetti dello stress su stomaco e intestino, secondo uno studio della rivista Plos one, si è rivelata in grado di far ricrescere i capelli.

Gli scienziati del Centro di Ricerca per le Patologie del Sistema Digerente del’Università della California stavano infatti effettuando degli esperimenti su alcune cavie per testare l’efficacia di una nuova sostanza, battezzata astressina-B e studiata per limitare gli effetti dello stress sull'apparato gastrointestinale.

A tale scopo gli scienziati avevano creato delle cavie geneticamente modificate per produrre in grandi quantità l’ormone che induce nell’organismo una risposta agli stress.

Più alta è la sua presenza, più l’individuo si stressa facilmente.

L’astressina-B era stata pensata per intervenire nel processo di liberazione di questo ormone, bloccandone il rilascio e quindi riducendo lo stress nell’individuo.

Le cavie “stressate”, che erano visibilmente malconce ed avevano iniziato a perdere il loro pelo dopo poche settimane di vita, erano state cresciute assieme ad un gruppo di controllo, dal pelo folto e scuro ed in perfette condizioni di salute.

Giunti al momento della sperimentazione, i ricercatori hanno iniettato per 5 giorni l’astressina-B nelle cavie stressate e calve e li hanno quindi rimessi assieme al gruppo di controllo.

Tuttavia, una volta passati 3 mesi e giunto il momento di verificare l’impatto del trattamento sull’apparato gastrointestinale, i ricercatori non sono più stati in grado di distinguere i topi “malati” da quelli sani: alle cavie trattate con astressina-B era infatti cresciuto un folto manto peloso e ora si rivelavano irriconoscibili da quelle del gruppo di controllo.

Million Mulugeta, coordinatore della ricerca, racconta: "Abbiamo guardato dentro la gabbia e in un primo momento ci siamo chiesti perché i topi calvi non c'erano, poi li abbiamo contati, e ci siamo resi conto che a tutte le cavie era cresciuto il pelo, è stata una scoperta del tutto inaspettata".

Secondo Mulugeta questa scoperta potrebbe costituire la base fondamentale di nuovi studi sull’astressina-B mirati a farne la prima rivoluzionaria cura contro la calvizie legata a stress e invecchiamento.

E' certamente presto per parlare di rimedi anticalvizie, dato che l'esperimento è stato condotto solo su cavie, che hanno cicli di ricrescita dei peli molto diversi dall'uomo, ma i risultati finora sono incoraggianti : i topi calvi dopo cinque giorni di iniezioni di questa sostanza, hanno recuperato in poche settimane un folto manto.

L'antistressina-B è un peptide di piccole dimensioni.

”Il nostro studio ha dimostrato che un trattamento per pochi giorni ha effetti a lungo termine sulla ricrescita dei peli spiega Million Mulugeta dell’universita’ della California a Los Angeles (Ucla), nell’uomo potrebbe essere indicato nei casi di perdita di capelli dovuta a stress ed età”.

”Gli effetti sull’uomo devono essere verificati, continua il ricercatore, che nel frattempo ha brevettato l’antistressina contro la calvizie, ma abbiamo visto che gli stessi topi trattati con un farmaco usato nell’uomo per la perdita di capelli hanno avuto una ricrescita molto inferiore, il che ci fa ben sperare per le applicazioni future”.

Certamente è da aspettare gli sviluppi delle ricerche perché nulla ancora si può dire.

 

Riferimenti studi scientifici

L'articolo originale della rivista PlosOne

Endocrinology, doi:10.1210/en.2007-1350
 

Astressin B, a Nonselective Corticotropin-Releasing Hormone Receptor Antagonist, Prevents the Inhibitory Effect of Ghrelin on Luteinizing Hormone Pulse Frequency in the Ovariectomized Rhesus Monkey

Department of Obstetrics and Gynecology (E.X., L.X.-Z., M.F.), College of Physicians and Surgeons, Columbia University, New York, New York 10032; Department of Obstetrics and Gynecology (N.R.V.), Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland; and The Salk Institute (J.R.), La Jolla, California 92307

Address all correspondence and requests for reprints to: Dr. Michel Ferin, Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, New York 10032. E-mail: mf8@columbia.edu.

Administration of ghrelin, a key peptide in the regulation of energy homeostasis, has been shown to decrease LH pulse frequency while concomitantly elevating cortisol levels. Because increased endogenous CRH release in stress is associated with an inhibition of reproductive function, we have tested here whether the pulsatile LH decrease after ghrelin may reflect an activated hypothalamic-pituitary-adrenal axis and be prevented by a CRH antagonist. After a 3-h baseline LH pulse frequency monitoring, five adult ovariectomized rhesus monkeys received a 5-h saline (protocol 1) or ghrelin (100-µg bolus followed by 100 µg/h, protocol 2) infusion. In protocols 3 and 4, animals were given astressin B, a nonspecific CRH receptor antagonist (0.45 mg/kg im) 90 min before ghrelin or saline infusion. Blood samples were taken every 15 min for LH measurements, whereas cortisol and GH were measured every 45 min. Mean LH pulse frequency during the 5-h ghrelin infusion was significantly lower than in all other treatments (P < 0.05) and when compared with the baseline period (P < 0.05). Pretreatment with astressin B prevented the decrease. Ghrelin stimulated cortisol and GH secretion, whereas astressin B pretreatment prevented the cortisol, but not the GH, release. Our data indicate that CRH release mediates the inhibitory effect of ghrelin on LH pulse frequency and suggest that the inhibitory impact of an insufficient energy balance on reproductive function may in part be mediated by the hypothalamic-pituitary-adrenal axis.

Astressin B, a Nonselective Corticotropin-Releasing Hormone Receptor Antagonist, Prevents the Inhibitory Effect of Ghrelin on Luteinizing Hormone Pulse Frequency in the Ovariectomized Rhesus Monkey Nicolas R Vulliémoz, Ennian Xiao, Linna Xia-Zhang, Jean Rivier, and Michel Ferin Department of Obstetrics and Gynecology (E.X., L.X.-Z., M.F.), College of Physicians and Surgeons, Columbia University, New York, New York 10032; Department of Obstetrics and Gynecology (N.R.V.), Centre Hospitalier Universitaire Vaudois, CH-1011 Lausanne, Switzerland; and The Salk Institute (J.R.), La Jolla, California 92307 Address all correspondence and requests for reprints to: Dr. Michel Ferin, Department of Obstetrics and Gynecology, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, New York, New York 10032. E-mail: mf8@columbia.edu. Received October 1, 2007; Accepted November 28, 2007. This article has been cited by other articles in PMC.   Abstract Administration of ghrelin, a key peptide in the regulation of energy homeostasis, has been shown to decrease LH pulse frequency while concomitantly elevating cortisol levels. Because increased endogenous CRH release in stress is associated with an inhibition of reproductive function, we have tested here whether the pulsatile LH decrease after ghrelin may reflect an activated hypothalamic-pituitary-adrenal axis and be prevented by a CRH antagonist. After a 3-h baseline LH pulse frequency monitoring, five adult ovariectomized rhesus monkeys received a 5-h saline (protocol 1) or ghrelin (100-μg bolus followed by 100 μg/h, protocol 2) infusion. In protocols 3 and 4, animals were given astressin B, a nonspecific CRH receptor antagonist (0.45 mg/kg im) 90 min before ghrelin or saline infusion. Blood samples were taken every 15 min for LH measurements, whereas cortisol and GH were measured every 45 min. Mean LH pulse frequency during the 5-h ghrelin infusion was significantly lower than in all other treatments (P < 0.05) and when compared with the baseline period (P < 0.05). Pretreatment with astressin B prevented the decrease. Ghrelin stimulated cortisol and GH secretion, whereas astressin B pretreatment prevented the cortisol, but not the GH, release. Our data indicate that CRH release mediates the inhibitory effect of ghrelin on LH pulse frequency and suggest that the inhibitory impact of an insufficient energy balance on reproductive function may in part be mediated by the hypothalamic-pituitary-adrenal axis.     GHRELIN, A 28-AMINO-ACID peptide, is the endogenous ligand of the GH secretagogue receptor (GHS-R) and is predominantly secreted by the stomach. Injection of ghrelin not only induces a potent GH release but also strongly stimulates appetite in rodents and humans. Ghrelin levels may increase during negative energy balance, a condition also known to inhibit reproductive axis activity. For example, high total ghrelin levels (about 1.4- to 2.6-fold of control levels) are reported in anorexia nervosa, a syndrome characterized by decreased food intake and amenorrhea. Central to energy deficiency-related reproductive dysfunction is a decreased LH pulse frequency. This is not surprising because a proper GnRH/LH pulse frequency is mandatory for the normal activity of the reproductive axis. Recent data suggest that ghrelin may play a role in mediating the inhibitory effect of a negative energy balance on the reproductive axis. Indeed, we have previously reported that a short-term peripheral ghrelin infusion in the ovariectomized (OVX) monkey significantly decreases LH pulse frequency. An acute inhibitory effect of ghrelin on LH pulse frequency has also been observed in the OVX rat, whereas a delay and a decrease in the amplitude of LH pulses have been reported in the male human. Peripheral infusion of ghrelin has been shown to stimulate cortisol release, suggesting an activation of the hypothalamic-pituitary-adrenal (HPA) axis by this peptide. Intriguingly, significant increases in cortisol levels are also observed in women showing decreases in LH pulsatility induced by a 5-d food restriction, and elevated ghrelin levels in patients with anorexia nervosa are accompanied by elevated cortisol levels. These observations suggest a potential linkage between activation of the HPA axis and the inhibition of reproductive function in a negative energy balance environment. Because a primary inhibitory role of central HPA pathways in the control of the reproductive axis during stress in the primate is well demonstrated, we have postulated that enhanced central HPA activity is causal to the inhibition of LH pulse frequency that follows ghrelin infusion. To verify this hypothesis, we have tested whether blocking endogenous CRH activity, using astressin B (a nonspecific CRH receptor antagonist), can prevent this inhibitory effect of ghrelin.   Materials and Methods Animals Five adult long-term OVX rhesus monkeys (Macaca mulatta) (body weight 5.0–8.5 kg) were used in this study. The animals were kept in individual cages in a temperature- and light-controlled room (lights on 0800–2000 h) and fed twice a day with a high-protein Purina monkey chow (Purina Mills, St. Louis, MO) supplemented with fresh fruit or vegetables. All animals participated in an active enrichment program provided by the staff of Veterinary Medicine. All procedures were approved by the Institutional Animal Care and Use Committee of Columbia University, and the research was conducted in accord with the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act. Experimental protocols Monkeys were briefly sedated with ketamine (5–7 mg/kg; Ketaset, Ford Dodge, IA) in the early morning, and catheters were inserted into both saphenous veins for blood sampling and infusions. The animals were then seated in a primate chair (to which they had previously been habituated), and the experiment was initiated about 1.5 h later, at which time they were fully awake. Each experiment lasted 8 h and included first a 3-h baseline control period followed by a 5-h treatment period. Blood samples (1.2 ml) were taken at 15-min intervals for hormone measurements. During the experiment, animals received fruits and snacks. They were returned to their home cages after the end of each experimental protocol and fed with their daily amount of food. To investigate the role of CRH in mediating the inhibitory effect of ghrelin on LH pulse frequency, four experimental protocols were performed in each monkey; after a 3-h control period to determine the baseline pulsatile LH release pattern, animals received a 5-h saline iv infusion (1 ml/h, protocol 1), a 5-h iv infusion of ghrelin (100 μg/h bolus, followed by 100 μg/h, protocol 2), ghrelin together with astressin B, a nonspecific CRH receptor antagonist (0.45 mg/kg in one injection im 90 min before the initiation of the ghrelin infusion, protocol 3), or astressin B injected 90 min before a saline infusion (protocol 4). Each animal underwent all experimental protocols in random order (except one monkey not tested under protocol 4), and at least 2 wk elapsed between two protocols. Human acylated ghrelin and astressin B were synthesized in the laboratory of J.R. Doses of ghrelin and astressin B used were shown in previous studies to be effective in the rhesus monkey. Assays and data analysis Blood samples were centrifuged, and sera were kept at −20 C until assay. LH was measured in all samples by a recombinant homologous RIA (reagents provided by Dr. A. F. Parlow, Pituitary Hormones and Antisera Center, Torrance, CA) in duplicate, as described previously. Assay sensitivity was 0.06 ng/ml. Intra- and interassay coefficients of variation (CV) were 4.5 and 12.6%, respectively. Cortisol and GH were measured in every fourth sample. Cortisol levels were assayed by RIA (Diagnostic Systems Laboratories/Beckham, er, TX) in duplicate. Intra- and interassay CV were 4.0 and 7.5%, respectively. All samples from individual animals were measured in the same assay. GH was measured by a chemiluminescent immunoassay (Immulite System; Diagnostic Products Corp./Siemens, Los Angeles, CA). Intraassay CV was 3.4%. Total ghrelin levels during infusion were measured in duplicate by RIA (Millipore Corp., St. Charles, MO) in hourly pooled samples. All samples were measured in one assay, with an intraassay CV of 3.3%. Mean LH pulse frequency, LH pulse amplitude, and LH concentrations were calculated. LH pulse frequency during the treatment periods in the four protocols was analyzed by one-way ANOVA with repeated measures followed by the Newman-Keuls multiple comparison test. The differences between baseline and the treatment periods were compared by Student’s t test. Three criteria were used for LH pulsatility analysis, as described previously : 1) the LH peak occurs within 30 min from the previous nadir; 2) the peak level from the previous nadir must be 3-fold greater than the intraassay CV; and 3) the LH increase must be followed by declining levels in accord with LH half-life. This approach to identify LH pulses was previously verified by the Cluster pulse-detection algorithm program. LH peaks that occurred at time 0 were included as pulses in the baseline period, because the treatments were initiated after the time 0 sample. Mean cortisol and GH levels, their percent changes from baseline at each time point, and areas under the curves in response to treatment were calculated. Differences between baseline and treatment and between treatments in the four protocols were analyzed by one-way ANOVA (Kruskal-Wallis nonparametric test) followed by the Dunn’s test. Mean hourly ghrelin changes during ghrelin infusion were calculated and compared by ANOVA. All statistical analyses were performed using PRISM (GraphPad, San Diego, CA).   Results Mean LH pulse frequency during the 5-h ghrelin treatment was significantly lower than that in the other three treatments: 0.60 ± 0/h (P < 0.05 vs. 0.96 ± 0.07/h in saline and 0.92 ± 0.05/h and 0.87 ± 0.07/h in ghrelin and saline with pretreatment of astressin B, respectively)). When compared with the 3-h baseline period, ghrelin infusion significantly decreased LH pulse frequency (P < 0.05); this decrease was prevented by astressin B administration. LH pulse frequency remained unchanged during saline infusion (with or without astressin B pretreatment). There were no significant changes in LH pulse amplitude or LH concentrations in any of the treatments.     The decrease in LH pulse frequency induced by a 5-h ghrelin infusion (100-μg bolus followed by 100 μg/h) is prevented by astressin B (a CRH receptor antagonist) pretreatment. LH pulse frequency during ghrelin treatment was significantly     Cortisol levels significantly increased 45 and 90 min after initiation of the ghrelin treatment (126.0 ± 10.8% and 125.7 ± 8.1% of baseline, respectively, P < 0.05). Pretreatment with astressin B prevented ghrelin stimulation of cortisol release. Mean area under the cortisol curve after astressin pretreatment was significantly lower than that after ghrelin alone and similar to that after saline or saline plus astressin B.     GH levels significantly increased 45 min after ghrelin injection (2126 ± 628.2% of baseline, P < 0.05; n = 4). In contrast to cortisol, astressin B did not prevent the stimulatory effect of ghrelin on GH release. Mean area under the GH curves in response to ghrelin infusions (with or without astressin B) were significantly higher than saline infusion. Astressin B itself did not show any effect on GH release . Total ghrelin levels remained stable during the 3-h baseline period (754.2 ± 38.8 pg/ml). Ghrelin infusion significantly increased ghrelin levels: by 5 h, mean ghrelin had increased to 3.29-fold of baseline, whereas overall increase over the 5-h infusion period was 1.76-fold of baseline .   Discussion The data confirm our previous observations that a short-term ghrelin infusion, elevating total ghrelin levels to 1.76-fold of baseline over a 5-h period, significantly decreases LH pulse frequency in the OVX nonhuman primate. We also confirm that ghrelin activates the HPA axis as shown by the increase in cortisol. Most importantly, we report for the first time that pretreatment with astressin B, a nonspecific CRH antagonist, prevents this inhibitory effect of ghrelin on LH pulse frequency and concomitantly suppresses the cortisol increase. The pivotal observation in this study is that blockage of endogenous CRH activity by a CRH receptor antagonist entirely prevents the suppressive effects of a short-term elevation of ghrelin levels on LH pulse frequency. Because the cortisol response to ghrelin is also prevented, it is likely that there exists a causal relationship between an activation of the HPA axis and the decrease in LH pulsatile activity. Because our antagonist is specific to CRH and because other investigators have shown that ghrelin releases CRH from rat hypothalamic explants , the data suggest a central role for CRH in mediating inhibitory effects of ghrelin on pulsatile LH release. A large body of evidence has already demonstrated a primary inhibitory role of CRH on the GnRH pulse generator and on the reproductive axis in several species. In the monkey, antagonism of endogenous CRH activity also readily prevents the decrease in pulsatile LH release after an acute stress challenge in OVX animals and accelerates the return to normal cyclic activity after a more chronic stress . The results from the present study suggest, for the first time, a mediatory role of CRH in the disruption of an essential element in reproductive function, i.e. the GnRH pulse generator, under conditions other than under stress challenges, such as in a negative energy balance condition. The overall increase in total ghrelin levels during our ghrelin infusions was 1.76-fold of baseline, within the reported range of total ghrelin levels in patients with anorexia nervosa , a syndrome that includes malnutrition as well as elevated cortisol levels. These patients also show a decreased activity of the GnRH pulse generator. An 85% increase in ghrelin level was reported in amenorrheic athletes and uniquely discriminated these subjects from those with less severe cyclic disturbances of exercising women. In the present study in the nonhuman primate, LH pulse frequency decreased from one pulse/63 min during the control saline infusion to one pulse/100 min during the 5-h ghrelin infusion, whereas CRH antagonist pretreatment restored it to one pulse/65 min. This effect might at first view appear modest. However, experiments in the monkey have clearly shown that small changes in GnRH pulse frequency in the range of those induced here by the 5-h ghrelin infusion do over a more chronic timeline significantly interfere with the normal reproductive cycle . In this regard, we believe that restoration to a normal LH pulse frequency by astressin B is a physiologically relevant observation. Like the modest suppression of LH pulse frequency induced by ghrelin infusions in the present study, cortisol increases were moderate compared with much steeper elevations observed in previous experiments in the monkey that included acute inflammatory stress challenges in which mean cortisol levels increased by 60% from baseline. However, this more potent activation of the HPA axis was accompanied by a remarkably deeper suppression of LH pulsatility. Significant in this aspect is the demonstration by Loucks and Thuma that LH pulse frequency inhibition after graded energy deficits is proportional to the increase in cortisol levels. The smaller inhibitory effect of ghrelin on LH pulse frequency in the present experiment most probably reflects the lower degree of activation of the HPA axis and of central CRH release and is presumably more representative of the finer tuning process exerted by the HPA axis on the reproductive system. The pathways by which peripherally secreted ghrelin stimulates the HPA axis and whether ghrelin directly activates centrally located CRH neurons remain to be fully investigated in both the acute and chronic condition. However, there is good evidence suggesting that hypothalamic neuropeptide Y (NPY)/agouti-related peptide (AGRP) neurons mediate the effects of ghrelin. We know, for instance, that NPY/AGRP neurons express GHS-R , that ghrelin administration in the rodent increases the synthesis of both NPY and AGRP mRNA levels, and that synthesis of these two peptides is increased in a negative energy balance environment . Like ghrelin, both AGRP and NPY exert a powerful orexigenic effect in the rodent and the monkey, and the orexigenic action of ghrelin is abolished in double-knockout NPY and AGRP mice. Data in the OVX monkey have also shown that NPY or AGRP infusions into the third ventricle readily inhibit pulsatile LH . These two neuropeptides have also been shown to stimulate the HPA axis. Finally, in the rat, NPY/AGRP neurons located in the arcuate nucleus of the hypothalamus densely innervate paraventricular CRH-containing neurons. Overall, the data suggest that activation of the HPA axis by elevated ghrelin is mediated by a NPY/AGRP-induced CRH release, which is in turn responsible for the decline in LH pulse frequency. Ghrelin, an acylated peptide, was first discovered as the endogenous ligand of the GHS-R, and as expected, our data show that there is a brief but significant increase in GH release during ghrelin infusion, as shown by others. In contrast to its effect on the cortisol increase that it abolishes, the CRH antagonist has no effect on the GH response to ghrelin, indicating that astressin B does not interfere with the bioactivity of ghrelin. Recently, a study has shown that chronic administration of unacylated ghrelin, initially thought of as an inert form of the hormone because it failed to modify GH secretion, can fully mimic the inhibitory effect of acylated ghrelin on LH and FSH release in the rat. These data highlight the fact that the effects of ghrelin on the somatotropic and gonadotropic axes are mediated by different pathways. In conclusion, we have demonstrated that pretreatment with astressin B, a nonspecific CRH antagonist, prevents the inhibitory effect of ghrelin on LH pulse frequency. These data demonstrate that the deleterious impact of ghrelin and possibly of a negative energy balance on the GnRH pulse generator and the reproductive axis is at least partially mediated by the central HPA axis. It should be pointed out, however, that the present data were obtained in an acute study and that a potential role of ghrelin and of the HPA axis in long-term situations remains to be explored. The data also suggest that the use of a CRH antagonist may provide a novel treatment approach in patients with reproductive dysfunction caused by an activated HPA axis. What has not been fully appreciated until recently in the human is the frequent association of elevated cortisol and reproductive dysfunction. Increased circulating and central cortisol levels are reported in most women with the functional chronic hypothalamic anovulation syndrome, a main cause of infertility classically associated with lifestyle changes that include not only energy deficiency but also psychogenic stress and strenuous exercise. Not only is an activated HPA axis common to functional chronic hypothalamic anovulation syndrome patients, but metabolic aberrations have also been frequently observed. In these patients, the role of the HPA axis in integrating a metabolic signal, such as that from ghrelin, in the fine-tuning process of the reproductive system remains to be fully investigated.   This work was supported by National Institutes of Health Grants RO1-HD-46715 (M.F.) and PO1-DK-26741 (J.R.). J.R. is the Dr. Frederik Paulsen Chair in Neurosciences Professor. Disclosure Statement: N.R.V., E.X., L.X.-Z., and M.F. have nothing to disclose. J.R. is founder of Sentis Medical Sciences. First Published Online December 6, 2007 See editorial p. 867. Abbreviations: CV, Coefficients of variation; GHS-R, GH secretagogue receptor; HPA, hypothalamic-pituitary-adrenal; OVX, ovariectomized.

Riferimenti bibliografici